312637-48-2

Usage

Uses

Used in Pharmaceutical Industry:
THIQ is used as a therapeutic agent for regulating energy homeostasis, eating behavior, and sexual functions. It acts as a potent and selective melanocortin 4 receptor agonist, modulating the activity of parasympathetic preganglionic neurons in the brainstem and regulating sympathetic and parasympathetic preganglionic neurons.

Biological Activity

Potent and selective melanocortin 4 (MC 4 ) receptor agonist (IC 50 values are 1.2, 761 and 2067 nM for human MC 4 , MC 3 and MC 1 receptors respectively). Enhances intracavernosal pressure and stimulates erectile activity in rats ex copula following systemic administration.

Upstream product

• 312638-92-9 4-cyclohexyl-4-(1H-1,2,4-triazol-1-yl-methyl)piperidine 
• 252008-71-2 (N-tert-butoxycarbonyl-D-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-4-chloro-D-phenylalanine 
• 475094-99-6 [1-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazole-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]carbamic acid tert-butyl ester 
• 312639-10-4 (2R)-3-(4-chlorophenyl)-1-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-1-oxo-propan-2-amine 
• 312638-89-4 4-cyclohexyl-4-methanesulfonyloxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 475094-98-5 4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 312638-87-2 4-cyclohexyl-4-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 624732-70-3 (4-cyclohexylpiperidin-4-yl)-methanol 
• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 77-17-8 Normeperidine 
• 4220-08-0 (4-phenyl-piperidin-4-yl)-methanol 
• 475095-00-2 [1-(4-chloro-benzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 852319-26-7 2-amino-3-(4-chlorophenyl)-1-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-propan-1-one 

Relevant academic research and scientific papers

PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY

The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1- (4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl) piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist

Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.